Anabolic skeletal therapy for osteoporosis

Girotra, Monica; Rubin, Mishaela R.; Bilezikian, John P.

doi:10.1590/s0004-27302006000400019

Cited by 20 publications

(10 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be one option for treating osteoporosis in men because it is associated with major gains in BMD at the lumbar spine, but less at the hip 4,14,80,84–86. Bone formation markers also increased with this treatment, and the risk of fracture reduced by 51% 87.…”

Section: Treatment Optionsmentioning

confidence: 99%

Causes, consequences, and treatment of osteoporosis in men

Banu¹

2013

DDDT

View full text Add to dashboard Cite

Men undergo gradual bone loss with aging, resulting in fragile bones. It is estimated that one in five men will suffer an osteoporotic fracture during their lifetime. The prognosis for men after a hip fracture is very grim. A major cause is reduction of free testosterone. Many other factors result in secondary osteoporosis, including treatment for other diseases such as cancer and diabetes. Patients should be screened not only for bone density but also assessed for their nutritional status, physical activity, and drug intake. Therapy should be chosen based on the type of osteoporosis. Available therapies include testosterone replacement, bisphosphonates, and nutritional supplementation with calcium, vitamin D, fatty acids, and isoflavones, as well as certain specific antibodies, like denosumab and odanacatib, and inhibitors of certain proteins.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%

Causes, consequences, and treatment of osteoporosis in men

Banu¹

2013

DDDT

View full text Add to dashboard Cite

show abstract

“…(18) The anabolic action of PTH on bone has been validated in humans(19–21) and its antifracture efficacy established in postmenopausal osteoporotic women. (22) At present, however, the physiologic basis of PTH anabolism remains unclear.…”

Section: Introductionmentioning

confidence: 99%

The calcium-sensing receptor mediates bone turnover induced by dietary calcium and parathyroid hormone in neonates

Shu

Zhu

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

We have investigated, in neonates, whether the calcium-sensing receptor (CaR) mediates the effects of dietary calcium on bone turnover and/or modulates parathyroid hormone (PTH)–induced bone turnover. Wild-type (WT) pups and pups with targeted deletion of the Pth (Pth–/–) gene or of both Pth and CaR (Pth–/–CaR–/–) genes were nursed by dams on a normal or high-calcium diet. Pups nursed by dams on a normal diet received daily injections of vehicle or of PTH(1–34) (80 µg/kg) for 2 weeks starting from 1 week of age. In pups receiving vehicle and fed by dams on a normal diet, trabecular bone volume, osteoblast number, type 1 collagen–positive area, and mineral apposition rate, as well as the expression of bone-formation-related genes, all were reduced significantly in Pth–/– pups compared with WT pups and were decreased even more dramatically in Pth–/–CaR–/– pups. These parameters were increased in WT and Pth–/– pups but not in Pth–/–CaR–/– pups fed by dams on a high-calcium diet compared with pups fed by dams on a normal diet. These parameters also were increased in WT, Pth–/–, and Pth–/–CaR–/– pups following exogenous PTH treatment; however, the percentage increase was less in Pth–/–CaR–/– pups than in WT and Pth–/– pups. In vehicle-treated pups fed by dams on either the normal or high-calcium diet and in PTH-treated pups fed by dams on a normal diet, the number and surfaces of osteoclasts and the ratio of RANKL/OPG were reduced significantly in Pth–/– pups and less significantly in Pth–/–CaR–/– pups compared with WT pups. These parameters were further reduced significantly in WT and Pth–/– pups from dams fed a high-calcium diet but did not decrease significantly in similarly treated Pth–/–CaR–/– pups, and they increased significantly in PTH-treated pups compared with vehicle-treated, genotype-matched pups fed by dams on the normal diet. These results indicate that in neonates, the CaR mediates alterations in bone turnover in response to changes in dietary calcium and modulates PTH-stimulated bone turnover. © 2011 American Society for Bone and Mineral Research.

show abstract

“…Anabolic agents positively affect a number of skeletal properties besides bone density (2). Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group of agents.…”

Section: Introductionmentioning

confidence: 99%

The use of PTH in the treatment of osteoporosis

Borba

Mañas

2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

SUMMARYAnabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metab. 2010;54(2):213-9 Keywords Osteoporosis; PTH; teriparatide; anabolic SUMÁRIOAs drogas anabólicas ampliaram recentemente as opções terapêuticas no tratamento da osteoporose e influenciam em maior escala os processos relacionados com a formação óssea, que ocorrem antes do efeito na reabsorção. Essas drogas afetam um grande número de propriedades esqueléticas, além da densidade mineral óssea. A administração intermitente de PTH leva a um aumento do número e atividade dos osteoblastos, ocasionando aumento da massa óssea e melhora da arquitetura, tanto do osso trabecular quanto cortical. O paratormônio recombinante humano (hrPTH 1-84) e o peptídeo recombinante humano 1-34 (teriparatide) pertencem a esse grupo de agentes. O objetivo deste artigo é revisar as ações, os benefícios e os efeitos adversos do PTH, assim como sua ação nos marcadores bioquímicos do metabolismo ósseo, a terapia combinada com drogas antirreabsortivas, o impacto do uso dos antirreabsortivos antes do tratamento anabólico, o tratamento sequencial e o tratamento da osteoporose induzida por glicocorticoides. Arq Bras Endocrinol Metab. 2010;54(2):213-9 Descritores Osteoporose; PTH, teriparatida, anabólico

show abstract

Anabolic skeletal therapy for osteoporosis

Cited by 20 publications

References 56 publications

Causes, consequences, and treatment of osteoporosis in men

Causes, consequences, and treatment of osteoporosis in men

The calcium-sensing receptor mediates bone turnover induced by dietary calcium and parathyroid hormone in neonates

The use of PTH in the treatment of osteoporosis

Contact Info

Product

Resources

About